Cardiovascular device company Translumina has acquired Wellinq group company Blue Medical Devices in the Netherlands for an undisclosed sum.

Established in 2013, Blue Medical Devices manufactures balloon catheters, including drug-coated balloons (DCB), along with other speciality balloons for complex coronary interventions.

The acquisition allows Translumina to utilise Blue Medical’s patented drug application technology in its other product lines in neurovascular and peripheral interventions and drug coating recipes.

The technology avoids any drug loss during the device advancement to the lesion, helping to deliver a high drug concentration at the targeted site.

Wellinq CEO Sander Hartman said: “We are convinced that Blue Medical's next-generation DCB catheters have a tremendous market opportunity with the global sales and marketing network of Wellinq's long-term partner Translumina.”

Blue Medical has developed Protégé NC and Protégé SC DCB catheters to better overcome current DCB technologies limitations, as well as provide high safety and efficacy.

The EU-MDR-approved catheters offer both non-compliant and semi-compliant versions.

Translumina Global Business Group CEO Indranil Mukherjee said: “I am excited to lead Translumina in this new wave of creating global leadership with path-breaking technologies.

“Our German lineage now makes further inroads in Europe with this move to the Netherlands, enabling us to offer a broad range of therapy solutions and disruptive innovations that address the unmet patient needs.”

Translumina, which is a fully integrated product development and manufacturing company, has facilities in India and Germany.